The adverse prognostic markers in MB (CDK6 SLC16A1D) are regulated by miR-124 Overexpression of the tumor suppressor miR124 decreases MB cell growth
in vitro and in xenograft tumors in mice suggesting possible use of miR-124 restoration in MB therapy. Here, CDK6 is linked to neoplasm.